Analystreport

CymaBay Therapeutics Inc (NASDAQ: CBAY) had its price target lowered by analysts at B. Riley from $2.00 to $1.50. They now have a "neutral" rating on the stock.

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com